Anti-Glypican 3 Antibody

Abstract

An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.

1 .- 32 . (canceled) 
     
     
         33 . Nucleic acid comprising a sequence that encodes a polypeptide comprising an anti-glypican 3 antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 84, 85, 86, 87, 88, 89, or 90. 
     
     
         34 . The nucleic acid of  claim 33 , wherein the nucleic acid comprises a sequence that encodes a polypeptide comprising an anti-glypican 3 antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 92, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, or 205. 
     
     
         35 . An expression vector comprising the nucleic acid of  claim 33 . 
     
     
         36 . A host cell comprising the nucleic acid of  claim 33 . 
     
     
         37 . Nucleic acid comprising a sequence that encodes a polypeptide comprising an anti-glypican 3 antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 92, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, or 205. 
     
     
         38 . An expression vector comprising the nucleic acid of  claim 37 . 
     
     
         39 . A host cell comprising the nucleic acid of  claim 37 . 
     
     
         40 . A set of one or more nucleic acids that together encode an anti-glypican 3 antibody that comprises:
 (a) an antibody heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences of SEQ ID NOs: 123, 124, 125, respectively, or   (b) an antibody light chain variable region having a CDR2 comprising the sequence of SEQ ID NO: 144, a CDR3 comprising the sequence of SEQ ID NO: 158, and a CDR1 comprising the sequence of SEQ ID NO: 143, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, or 188.   
     
     
         41 . An expression vector that comprises the set of nucleic acids of  claim 40 . 
     
     
         42 . A set of expression vectors that together comprise the set of nucleic acids of  claim 40 . 
     
     
         43 . A host cell comprising the set of nucleic acids of  claim 40 . 
     
     
         44 . The set of nucleic acids of  claim 40 , wherein the antibody is a humanized antibody. 
     
     
         45 . An expression vector that comprises the set of nucleic acids of  claim 44 . 
     
     
         46 . A set of expression vectors that together comprise the set of nucleic acids of  claim 44 . 
     
     
         47 . A host cell comprising the set of nucleic acids of  claim 44 . 
     
     
         48 . A peptide comprising the amino acid sequence of amino acid residues 524-563, amino acid residues 537-563, amino acid residues 544-553, or amino acids residues 546-551 of glypican 3.